【券商聚焦】交银国际:继续看好研发能力较强的创新药企 予中国生物制药、康方生物及药明生物“买入”评级

凤凰网港股
06 Jan 2021

原标题:【券商聚焦】交银国际:继续看好研发能力较强的创新药企 予中国生物制药、康方生物及药明生物“买入”评级 来源:凤凰网港股凤凰网港股|交银国际发布医药行业周报(截至2020年1月5日),公司方面:复星医药(02196HK)呋塞米片、替米沙坦片通过一致性评价。东阳光药(01558HK)苯甲酸阿格列汀片、磷酸依米他韦获批上市。上海医药(02607HK)用于治疗溃疡性结肠炎SPH3127在美临床试验...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10